Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Semanti Mukherjee, Chaitanya Bandlamudi, Matthew D. Hellmann, Yelena Kemel et autres
0 citations
Gareth L. Bond
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
139Publications signalées
5116Citations signalées
0Affiliations récentes
Les domaines associés
Cancer-related Molecular PathwaysEpigenetics and DNA MethylationRNA modifications and cancerCancer Genomics and DiagnosticsHIV/AIDS drug development and treatment
Les publications récentes
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Semanti Mukherjee, Chaitanya Bandlamudi, Matthew D. Hellmann, Yelena Kemel et autres
0 citations
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Semanti Mukherjee, Chaitanya Bandlamudi, Matthew D. Hellmann, Yelena Kemel et autres
0 citations
Supplementary Figure 2E from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Supplementary Figure 3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Table S3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Supplementary Figure 1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Figure 6 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Supplementary Figure 5 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Supplementary Materials from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
Figure 5 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.